SCHEMBL6445232

SCHEMBL6445232

N#Cc1c(NCCN2CCOCC2)nc(N)nc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.56
ADORA1 P30542 3/20 0.54
ADORA2A P29274 2/20 0.54
HIF1A Q16665 1/20 0.53
CYP3A4 P08684 4/20 0.52
CYP1A2 P05177 3/20 0.52
CYP2D6 P10635 3/20 0.52
CYP2C19 P33261 2/20 0.52
CLK4 Q9HAZ1 2/20 0.52
ALDH1A1 P00352 2/20 0.52
USP2 O75604 1/20 0.52
MAPK1 P28482 1/20 0.52
TLR9 Q9NR96 3/20 0.51
LMNA P02545 3/20 0.48
CHRM1 P11229 2/20 0.48
CNR1 P21554 1/20 0.48
HTR2B P41595 1/20 0.48
KCNH2 Q12809 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6444222 0.85 ALDH1A1 (0.63) ACHEADORA1ADORA2AHIF1ACYP3A4
SCHEMBL6443228 0.84 ALDH1A1 (0.57) ACHEADORA1ADORA2ACYP3A4CYP1A2
SCHEMBL6441934 0.83 ADORA1 (0.55) ACHEADORA1ADORA2ACYP3A4CYP1A2
SCHEMBL10706449 0.80 ACHE (0.62) ACHEHIF1ACYP3A4CYP1A2CYP2D6
SCHEMBL6441739 0.78 ADORA1 (0.61) ADORA1ADORA2A
SCHEMBL6443028 0.77 ADORA1 (0.60) ADORA1ADORA2AALDH1A1TDP1KDM4E
SCHEMBL6443635 0.75 ADORA1 (0.57) ADORA1ADORA2AALDH1A1LMNAKDM4E
SCHEMBL6446329 0.75 ALDH1A1 (0.52) ADORA1ADORA2AHIF1AALDH1A1LMNA
SCHEMBL14233404 0.75 TLR9 (0.71) HIF1ACYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL6447580 0.75 KDM4E (0.75) ADORA1ADORA2AALDH1A1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ACHE 39/4885ADORA1 3/4885ADORA2A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.